Table 1 Clinicopathological characteristics of PTCL patients according to TCLlnc1 expression in serum (n = 138)a.
Variables | Low TCLlnc1 (n = 69) | High TCLlnc1 (n = 69) | P value |
|---|---|---|---|
Gender | 0.4650 | ||
Female | 20 (29%) | 24 (35%) | |
Male | 49 (71%) | 45 (65%) | |
Age (years) | 0.1677 | ||
<60 | 44 (64%) | 36 (52%) | |
≥60 | 25 (36%) | 33 (48%) | |
ECOG | 0.8127 | ||
0–1 | 58 (84%) | 59 (86%) | |
≥2 | 11 (16%) | 10 (14%) | |
LDH level | 0.4823 | ||
Normal | 24 (35%) | 28 (41%) | |
Elevated | 45 (65%) | 41 (59%) | |
Extranodal involvement | 0.0152 | ||
<2 | 48 (70%) | 34 (49%) | |
≥2 | 21 (30%) | 35 (51%) | |
Ann Arbor stage | 0.2359 | ||
I–II | 20 (29%) | 14 (20%) | |
III–IV | 49 (71%) | 55 (80%) | |
IPI | 0.0063 | ||
Low risk | 45 (65%) | 29 (42%) | |
High risk | 24 (35%) | 40 (58%) | |
Response to treatment | 0.0006 | ||
CR | 41 (59%) | 21 (30%) | |
Non-CR | 28 (41%) | 48 (70%) |
